Selected Start-Ups (4/03)
In Vivo briefly summarizes the technologies of these recently founded companies: AdvanDx Inc., AngioDesign Inc., Chiasma Inc., Ocularis Pharma Inc., Trism Inc. and Zelos Therapeutics Inc.
You may also be interested in...
Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.
The latest big pharma vote of confidence in both the China market and R&D capabilities comes amid continuing standoffs with the US over a flurry of issues including the coronavirus, national security and trade, but as the pandemic seemingly recedes in China.